Key Insights

Highlights

Success Rate

91% trial completion (above average)

Published Results

16 trials with published results (24%)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

6.1%

4 terminated out of 66 trials

Success Rate

90.9%

+4.4% vs benchmark

Late-Stage Pipeline

30%

20 trials in Phase 3/4

Results Transparency

40%

16 of 40 completed with results

Key Signals

16 with results91% success

Data Visualizations

Phase Distribution

43Total
Not Applicable (7)
P 1 (5)
P 2 (11)
P 3 (19)
P 4 (1)

Trial Status

Completed40
Unknown10
Active Not Recruiting8
Terminated4
Withdrawn2
Not Yet Recruiting1

Trial Success Rate

90.9%

Benchmark: 86.5%

Based on 40 completed trials

Clinical Trials (66)

Showing 20 of 20 trials
NCT05797246Phase 2Active Not Recruiting

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

NCT06919627Completed

Negative HPV Test Results on Infinity/GeneXpert® With the Presence of a Late Amplification Signal: What Does This Mean ? (PaPCR)

NCT02858310Phase 1CompletedPrimary

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

NCT05119855Phase 3CompletedPrimary

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

NCT04124198Not ApplicableActive Not Recruiting

Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma

NCT04694495CompletedPrimary

HPV Infection and Genital Microecology of Childbearing-age Female in China: A Cohort and Multicenter Study

NCT04724980Phase 1Active Not Recruiting

Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis

NCT04772534Phase 3CompletedPrimary

Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)

NCT04708041Phase 3Active Not RecruitingPrimary

Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)

NCT04199689Phase 3Active Not RecruitingPrimary

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

NCT03903562Phase 3CompletedPrimary

Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024)

NCT06859151Not Yet Recruiting

DNA Methylation and the Increased Risk of Cervical Cancer Development

NCT06854354Not ApplicableCompletedPrimary

Intervention for Human Papillomavirus Vaccine Acceptance in Mexican Mothers

NCT05285826Phase 3Active Not RecruitingPrimary

Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)

NCT03487549Phase 2Completed

Cantharidin and Occlusion in Verruca Epithelium

NCT03981822Phase 2Completed

A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts

NCT06700941Completed

Impact of HPV Vaccination Against Cervical Lesions and Genital Warts in Colombia. an Ecological Assessment

NCT00501189WithdrawnPrimary

Gardasil Vaccination as Therapy in Low Grade Cervical Abnormalities

NCT06439433Phase 2Completed

ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection

NCT06371118Not ApplicableRecruitingPrimary

HPV Self-sampling for Women Who do Not Attend Cervical Cancer Screening Programme

Scroll to load more

Research Network

Activity Timeline